» Articles » PMID: 1787646

Role for "uremic Toxin" in the Progressive Loss of Intact Nephrons in Chronic Renal Failure

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 1991 Sep 1
PMID 1787646
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We studied the effect on the progression of glomerular sclerosis of two different experimental maneuvers, peritoneal dialysis and oral adsorbent, which remove circulating substances in different fashions. Munich-Wistar rats with established glomerular sclerosis, verified by renal biopsy analysis at seven weeks after subtotal nephrectomy, were treated for four weeks with either peritoneal dialysis (PD) or oral charcoal adsorbent (AST-120). Treatment was initiated at eight weeks. Rats were paired in treatment and control groups according to the similarity in the degree of sclerosis determined at biopsy with a minimum of 50 glomeruli analyzed. Systolic blood pressure and BUN and creatinine clearance, measured at seven to eight weeks, were not different among groups. In Group 2 rats, PD was performed with 1.5% dextrose for eight one-hour cycles, six days per week, while Group 1 control rats had zero indwelling time of the dialysate. Group 4 rats received AST-120, an oral adsorbent charcoal, mixed 5% by weight with standard rat chow and given ad libitum from 8 to 12 weeks after subtotal nephrectomy, while control Group 3 rats received only rat chow. Whole kidney GFR at 12 weeks was significantly higher in Group 2 PD versus Group 1 control (0.50 +/- 0.08 vs. 0.30 +/- 0.05 ml/min, P less than 0.05). There was no statistical difference for BUN and whole kidney creatinine or inulin clearance in Group 4 AST-120 treated versus Group 3 control rats. Light microscopic studies in autopsy specimens revealed that both PD and AST-120 attenuated progression of glomerular sclerosis.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Impact of using oral spherical carbon adsorbent in predialysis chronic kidney disease period on cardiovascular outcome after dialysis therapy.

Kweon T, Kee Y, Shin D, Oh J, Jeon H Sci Rep. 2025; 15(1):6315.

PMID: 39984620 PMC: 11845776. DOI: 10.1038/s41598-025-90779-6.


Transcriptomic analysis identifies novel candidates in cardiorenal pathology mediated by chronic peritoneal dialysis.

Nasci V, Liu P, Marks A, Williams A, Kriegel A Sci Rep. 2023; 13(1):10051.

PMID: 37344499 PMC: 10284882. DOI: 10.1038/s41598-023-36647-7.


Influence of Modified Carbon Black on Nylon 6 Nonwoven Fabric and Performance as Adsorbent Material.

Andrade-Guel M, Reyes-Rodriguez P, Cabello-Alvarado C, Cadenas-Pliego G, Avila-Orta C Nanomaterials (Basel). 2022; 12(23).

PMID: 36500869 PMC: 9735733. DOI: 10.3390/nano12234247.


Nanocomposite PLA/C20A Nanoclay by Ultrasound-Assisted Melt Extrusion for Adsorption of Uremic Toxins and Methylene Blue Dye.

Andrade-Guel M, Cabello-Alvarado C, Romero-Huitzil R, Rodriguez-Fernandez O, Avila-Orta C, Cadenas-Pliego G Nanomaterials (Basel). 2021; 11(10).

PMID: 34684919 PMC: 8537835. DOI: 10.3390/nano11102477.


Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.

Kee Y, Han S, Kang D, Noh J, Jeong K, Kim G Yonsei Med J. 2020; 62(1):41-49.

PMID: 33381933 PMC: 7820454. DOI: 10.3349/ymj.2021.62.1.41.